If you have played Plants vs Zombies and liked it, you’ll surely find Merge and Fight an interesting experience. This game merges the best points of a tower defense game and Plants vs Zombies to give ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Altitude Labs, a biotechnology accelerator backed by Recursion Pharmaceuticals, on Wednesday said it is launching a new fund to give pre-seed grants to life sciences researchers and startups disrupted ...

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community. Issues are used to track todos, bugs, feature requests, and more.

Merge sort is entirely different than the sorting algorithms we’ve seen so far, and it represents an important class of algorithms—divide-and-conquer algorithms. Divide-and-conquer algorithms work by ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...